EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSCHYG00000018306
Gene Symbol: DHCR24
1 Cross references
209 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSCHYG00000005715
Gene Symbol: HMGCR
1 Cross references
272 Possible Orthologues:

3-Phosphoinositide Dependent Protein Kinase 1

Ensembl ID : ENSCHYG00000004327
Gene Symbol: PDPK1
1 Cross references
244 Possible Orthologues:

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSCHYG00000004432
Gene Symbol: HPD
1 Cross references
207 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSCHYG00000020770
Gene Symbol: NT5E
1 Cross references
250 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSCHYG00000025432
Gene Symbol: HTR1A
1 Cross references
150 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSCHYG00000026182
Gene Symbol: HTR1B
1 Cross references
244 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSCHYG00000019905
Gene Symbol: HTR1E
1 Cross references
157 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSCHYG00000025282
Gene Symbol: HTR1F
1 Cross references
146 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSCHYG00000024474
Gene Symbol: HTR2A
1 Cross references
217 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSCHYG00000011019
Gene Symbol: HTR2B
1 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSCHYG00000024246
Gene Symbol: HTR2C
1 Cross references
226 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).